ArticleJAMA psychiatry2020
Findings From World Mental Health Surveys of the Perceived Helpfulness of Treatment for Patients With Major Depressive Disorder.
Article in JAMA psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 102 citations in OpenAlex.
- Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: a randomized double-blind, placebo-controlled clinical trial.BMC psychiatry · 2024Trial
- Leveraging machine learning to personalize depression treatment: A pre-registered study of 828 adults randomized to a digital single-session intervention or waitlist.Clinical psychological science : a journal of the Association for Psychological Science · 2026Article
- Intrinsic motivation to study and amotivation for most frequently performed activities: Association with increased non-specific psychological distress.PCN reports : psychiatry and clinical neurosciences · 2026Article
- Health system use and experience among people with poor mental health: A cross-sectional analysis of the People's Voice Survey in 18 countries.PLoS medicine · 2026Article
- Associations of perceived helpfulness of depression treatment modality with symptom severity and substance use disorder.Discover mental health · 2026Article
- Delays in diagnosis and treatment of depressive disorder among young adults: A national online survey-based cross-sectional study.PloS one · 2026Article
- Limitations of PHQ-9 as a first line mental health screener in primary care.Frontiers in psychiatry · 2026Article
- SolanoConnex: developing a web-app for accessing local, up-to-date mental health services in a diverse county.mHealth · 2026Article
- Patient Experience with Intranasal Esketamine in Treatment-Resistant Depression: Insights from a Multicentric Italian Study (REAL-ESKperience).Journal of personalized medicine · 2025Article
- Treatment resistant but not irremediable.Bipolar disorders · 2025Article
- Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023: Towards Personalized Approaches to Depression Treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2024Article
- Estimation of the Global Disease Burden of Depression and Anxiety between 1990 and 2044: An Analysis of the Global Burden of Disease Study 2019.Healthcare (Basel, Switzerland) · 2024Article
- Lifetime prevalence, risk, and treatment of mood and anxiety disorders in Qatar's national mental health study.International journal of methods in psychiatric research · 2024Article
- Negative life events and depression by gender in the Brazilian Longitudinal Study of Adult Health (ELSA-Brazil).Clinics (Sao Paulo, Brazil) · 2024Article
- Review
- Leveraging big data for causal understanding in mental health: a research framework.Frontiers in psychiatry · 2024Review
- Design and Implementation of Survey Quality Control System for Qatar's First National Mental Health Survey: Case Study.JMIR formative research · 2023Article
- The Patient's Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression.Brain sciences · 2023Article
- Identifying active ingredients in cognitive-behavioral therapies: What if we didn't?Behaviour research and therapy · 2023Article
- Evidence-Based Pharmacotherapy of Anxiety Symptoms in Patients with Major Depressive Disorder: Focus on Agomelatine.Neurology and therapy · 2023Article
Corrections and comments
- Commented on by
Authors and funding
29 authors at 20 institutions in 18 countries.
Funding
Abstract
Importance: The perceived helpfulness of treatment is an important patient-centered measure that is a joint function of whether treatment professionals are perceived as helpful and whether patients persist in help-seeking after previous unhelpful treatments. Objective: To examine the prevalence and factors associated with the 2 main components of perceived helpfulness of treatment in a representative sample of individuals with a lifetime history of DSM-IV major depressive disorder (MDD). Design, Setting, and Participants: This study examined the results of a coordinated series of community epidemiologic surveys of noninstitutionalized adults using the World Health Organization World Mental Health surveys. Seventeen surveys were conducted in 16 countries (8 surveys in high-income countries and 9 in low- and middle-income countries). The dates of data collection ranged from 2002 to 2003 (Lebanon) to 2016 to 2017 (Bulgaria). Participants included those with a lifetime history of treated MDD. Data analyses were conducted from April 2019 to January 2020. Data on socioeconomic characteristics, lifetime comorbid conditions (eg, anxiety and substance use disorders), treatment type, treatment timing, and country income level were collected. Main Outcomes and Measures: Conditional probabilities of helpful treatment after seeing between 1 and 5 professionals; persistence in help-seeking after between 1 and 4 unhelpful treatments; and ever obtaining helpful treatment regardless of number of professionals seen. Results: Survey response rates ranged from 50.4% (Poland) to 97.2% (Medellín, Columbia), with a pooled response rate of 68.3% (n = 117 616) across surveys. Mean (SE) age at first depression treatment was 34.8 (0.3) years, and 69.4% were female. Of 2726 people with a lifetime history of treatment of MDD, the cumulative probability (SE) of all respondents pooled across countries of helpful treatment after seeing up to 10 professionals was 93.9% (1.2%), but only 21.5% (3.2%) of patients persisted that long (ie, beyond 9 unhelpful treatments), resulting in 68.2% (1.1%) of patients ever receiving treatment that they perceived as helpful. The probability of perceiving treatment as helpful increased in association with 4 factors: older age at initiating treatment (adjusted odds ratio [AOR], 1.02; 95% CI, 1.01-1.03), higher educational level (low: AOR, 0.48; 95% CI, 0.33-0.70; low-average: AOR, 0.62; 95% CI, 0.44-0.89; high average: AOR, 0.67; 95% CI, 0.49-0.91 vs high educational level), shorter delay in initiating treatment after first onset (AOR, 0.98; 95% CI, 0.97-0.99), and medication received from a mental health specialist (AOR, 2.91; 95% CI, 2.04-4.15). Decomposition analysis showed that the first 2 of these 4 factors were associated with only the conditional probability of an individual treatment professional being perceived as helpful (age at first depression treatment: AOR, 1.02; 95% CI, 1.01-1.02; educational level: low: AOR, 0.48; 95% CI, 0.33-0.70; low-average: AOR, 0.62; 95% CI, 0.44-0.89; high-average: AOR, 0.67; 95% CI, 0.49-0.91 vs high educational level), whereas the latter 2 factors were associated with only persistence (treatment delay: AOR, 0.98; 95% CI, 0.97-0.99; treatment type: AOR, 3.43; 95% CI, 2.51-4.70). Conclusions and Relevance: The probability that patients with MDD obtain treatment that they consider helpful might increase, perhaps markedly, if they persisted in help-seeking after unhelpful treatments with up to 9 prior professionals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.